ClinicalTrials.gg
RecruitingNCT05464186Updated Jan 8, 2026

Effects of Whole vs. Nonfat Milk Consumption on Body Composition in Children

An interventional study of Whole milk and Nonfat milk in Obesity, Diabetes and Cardiovascular Diseases, sponsored by Boston Children's Hospital. Recruiting at 1 site in United States. Open to participants aged 9 Years to 12 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-08.

Sponsored by Boston Children's Hospital · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Dec 2022; still recruiting 3 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
9 Years to 12 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Obesity by Boston Children's Hospital — 2 open to participants now, 2 under way, none of them phase 3. Obesity · Boston Children's Hospital.

Planned enrollment
6th of 18
200 · median 123
Started
2022
the only one that year
No phase
19 of 19
2 open now
Registered
17th of 19
by date

Among the 19 studies in Obesity by Boston Children's Hospital, this one is the 6th largest by planned enrollment of the 18 interventional ones that give a count, is the only one that started in 2022, is one of 19 with no phase, and was the 17th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

2 of the 19 studies in Obesity by Boston Children's Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 9 Years to 12 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Obesity by Boston Children's Hospital, or all of them as a file.
02

Study summary

This study will evaluate the effects of whole vs. nonfat milk consumption on body composition, cardiometabolic disease risk factors, and dietary quality.

Read the detailed description

Background The optimal type of milk is a topic of much debate. Several recent observational studies indicate that consuming whole (full-fat), compared to reduced-fat milk, is associated with less weight gain and decreased cardiometabolic disease risk. The observed beneficial effect of consuming whole milk on body weight may be due to its greater satiety value, leading to consumption of fewer calories from other lower quality (e.g., sugary) foods. Mechanistic studies indicate that substitution of carbohydrate with certain saturated fatty acids in milk increases low-density lipoprotein cholesterol (LDL-C). However, this increase has been attributed to large, buoyant particles that are less atherogenic than small, dense particles; is accompanied by an increase in high-density lipoprotein cholesterol (HDL-C); and may not elevate overall risk compared to carbohydrate.

Specific Aims and Hypotheses

  • To examine the effects of milk consumption on body composition (Aim #1) and cardiometabolic disease risk factors (Aim #2). Primary Hypothesis. Consuming whole milk will result in less weight gain compared to consuming nonfat milk. Secondary hypothesis. Consuming whole milk will decrease cardiometabolic disease risk compared to consuming nonfat milk.
  • To explore the effects of milk consumption on dietary quality (Aim #3). Exploratory hypothesis. Consuming whole milk will improve overall dietary quality by displacing lower quality foods compared to consuming nonfat milk, particularly among children with low baseline dietary quality.
  • (Ancillary Study) To evaluate the effects of milk consumption on risk and prevalence of dental caries.

Design Randomized Controlled Trial. Participants (N=200, aged 9 to 12 years, BMI≥75th percentile) will be randomly assigned for 1 year to receive: 1) Whole milk, 3 cups/d or 2) Nonfat milk, 3 cups/d. To promote adherence to the interventions, the investigators will rely on home delivery of milk using methods consistent with previous successful studies.

Study Outcomes The primary outcome is change in fat mass measured by air displacement plethysmography (BodPod) at 3 time points (baseline and 6 and 12 months). To evaluate cardiometabolic disease risk factors, the investigators will obtain a plasma MetaboProfile®(LabCorp) that includes lipoprotein particle sizes and subfraction concentrations, novel measures of insulin-resistant dyslipoproteinemia and inflammation, and a conventional lipid profile. The investigators will also measure blood pressure.

For the Ancillary Study, outcomes include salivary cariogenicity (pH, flow, and buffering capacity); caries prevalence; dietary quality (cariogenic potential); and serum 25-hydroxyvitamin D.

03

Conditions studied

  • Obesity
  • Diabetes
  • Cardiovascular Diseases
04

Who can participate

Ages eligible
9 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 9 to 12 years
  • ≥75th percentile for sex and age
  • Residence in the Greater Boston catchment area

Exclusion criteria

Exclusion Criteria:

  • Aversion to nonfat or whole milk
  • Physician diagnosis of major medical illness, eating disorder, or milk allergy (lactose intolerance not exclusionary as lactase treated milk can be provided)
  • Plans to move away from the Greater Boston catchment area during the study period
  • Plans to be away from home for ≥5 weeks during the study period (e.g., extended summer vacation)
  • Change in body weight exceeding 10% during prior year
  • Recent adherence to a special diet
  • Chronic use of any medication or dietary supplement that could affect study outcomes
  • Another member of the family (first degree relative) or household participating in the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Whole milk

    3 cups a day of whole milk for 1 year

    Behavioral: Whole milk

  • Experimental
    Nonfat milk

    3 cups a day of nonfat milk for 1 year

    Behavioral: Nonfat milk

Interventions

  • BehavioralWhole milk

    Weekly home delivery of whole milk, daily text messages, monthly virtual visits

  • BehavioralNonfat milk

    Weekly home delivery of nonfat milk, daily text messages, monthly virtual visits

06

What researchers measure

Primary outcomes

  1. Fat mass

    Primary outcome for the overall study, main outcome for Specific Aim #1, measured by air displacement plethysmography (BodPod)

    Time frame: Change from start of trial (time of randomization) through end of trial (12 months)

Secondary outcomes

  1. Lean body mass

    Measured by air displacement plethysmography (BodPod)

    Time frame: Change from start of trial (time of randomization) through end of trial (12 months)

  2. Percent body fat

    Measured by air displacement plethysmography (BodPod)

    Time frame: Change from start of trial (time of randomization) through end of trial (12 months)

  3. Height

    Linear growth

    Time frame: Change from start of trial (time of randomization) through end of trial (12 months)

  4. Body mass index (BMI)

    Weight in kg divided by height in meters squared

    Time frame: Change from start of trial (time of randomization) through end of trial (12 months)

  5. Leptin

    "Satiety" hormone, released by fat cells, measured by ELISA assay

    Time frame: Change from start of trial (time of randomization) through end of trial (12 months)

  6. Ghrelin

    "Hunger" hormone, released primarily in the stomach, measured by ELISA assay

    Time frame: Change from start of trial (time of randomization) through end of trial (12 months)

  7. Insulin-like growth factor-1 (IGF-1)

    Indicator of growth hormone action, measured by ELISA assay

    Time frame: Change from start of trial (time of randomization) through end of trial (12 months)

  8. Insulin-like growth factor-binding protein 3 (IGF-BP3)

    Measured by ELISA assay

    Time frame: Change from start of trial (time of randomization) through end of trial (12 months)

  9. Lipoprotein insulin resistance (LPIR)

    Main outcome for Specific Aim #2; a 6-component weighted score of triglyceride-rich, high-density, and low-density lipoprotein particle (TRL-P, HDL-P, LDL-P) sizes and subfraction concentrations (sum of large and very large TRL-P, large HDL-P, small LDL-P), measured by nuclear magnetic resonance spectroscopy

    Time frame: Change from start of trial (time of randomization) through end of trial (12 months)

  10. Triglyceride-rich lipoprotein particle (TRL-P) size

    Measured by nuclear magnetic resonance spectroscopy

    Time frame: Change from start of trial (time of randomization) through end of trial (12 months)

  11. High-density lipoprotein particle (HDL-P) size

    Measured by nuclear magnetic resonance spectroscopy

    Time frame: Change from start of trial (time of randomization) through end of trial (12 months)

  12. Low-density lipoprotein particle (LDL-P) size

    Measured by nuclear magnetic resonance spectroscopy

    Time frame: Change from start of trial (time of randomization) through end of trial (12 months)

  13. Sum of large and very large TRL-P concentration

    Measured by nuclear magnetic resonance spectroscopy

    Time frame: Change from start of trial (time of randomization) through end of trial (12 months)

  14. Large HDL-P concentration

    Measured by nuclear magnetic resonance spectroscopy

    Time frame: Change from start of trial (time of randomization) through end of trial (12 months)

  15. Small LDL-P concentration

    Measured by nuclear magnetic resonance spectroscopy

    Time frame: Change from start of trial (time of randomization) through end of trial (12 months)

  16. Large LDL-P concentration

    Measured by nuclear magnetic resonance spectroscopy

    Time frame: Change from start of trial (time of randomization) through end of trial (12 months)

  17. Triglycerides (TG)

    Part of conventional lipid profile

    Time frame: Change from start of trial (time of randomization) through end of trial (12 months)

  18. High-density lipoprotein cholesterol (HDL-C)

    Part of conventional lipid profile

    Time frame: Change from start of trial (time of randomization) through end of trial (12 months)

  19. Low-density lipoprotein cholesterol (LDL-C)

    Part of conventional lipid profile

    Time frame: Change from start of trial (time of randomization) through end of trial (12 months)

  20. Glucose

    Measured enzymatically using hexokinase method

    Time frame: Change from start of trial (time of randomization) through end of trial (12 months)

  21. Insulin

    Measured by electrochemiluminescence immunoassay

    Time frame: Change from start of trial (time of randomization) through end of trial (12 months)

  22. Insulin resistance

    Measured by homeostasis model assessment (HOMA), using fasting glucose and insulin concentrations

    Time frame: Change from start of trial (time of randomization) through end of trial (12 months)

  23. Adiponectin - total and high molecular weight

    Hormone released from fat cells, promotes insulin sensitivity and helps regulate blood glucose, measured by ELISA assay

    Time frame: Change from start of trial (time of randomization) through end of trial (12 months)

  24. Hemoglobin A1c (HgA1c)

    Marker of blood glucose control, measured using a system based turbidimetric immunoinhibition

    Time frame: Change from start of trial (time of randomization) through end of trial (12 months)

  25. High-sensitivity C-reactive protein (hsCRP)

    Indicator of chronic inflammation, measured by immunoturbidimetric assay

    Time frame: Change from start of trial (time of randomization) through end of trial (12 months)

  26. Interleukin-6 (IL-6)

    Protein which stimulates synthesis of hsCRP, measured by ELISA assay

    Time frame: Change from start of trial (time of randomization) through end of trial (12 months)

  27. Fibrinogen

    Protein involved in blood clotting, measured by immunoturbidimetric assay

    Time frame: Change from start of trial (time of randomization) through end of trial (12 months)

  28. Plasminogen activator inhibitor-1 (PAI-1)

    Protein involved in blood clotting, measured by ELISA assay

    Time frame: Change from start of trial (time of randomization) through end of trial (12 months)

  29. Systolic blood pressure

    Measured by auscultation

    Time frame: Change from start of trial (time of randomization) through end of trial (12 months)

  30. Diastolic blood pressure

    Measured by auscultation

    Time frame: Change from start of trial (time of randomization) through end of trial (12 months)

  31. Salivary cariogenicity

    (Ancillary Study) Risk for dental caries (cavities), measured using the GC Dental America Saliva-Check Buffer Kit (pH, flow, and buffering capacity)

    Time frame: Change from start of trial (time of randomization) through end of trial (12 months)

  32. Caries prevalence

    (Ancillary Study) Assessed by clinical examination and digital radiograph (x-rays)

    Time frame: Difference between start of trial (time of randomization) and end of trial (12 months)

  33. Serum 25-hydroxyvitamin D [25(OH)D]

    (Ancillary Study) Measured by a competitive electrochemiluminescence immunoassay

    Time frame: Change from start of trial (time of randomization) through end of trial (12 months)

Other outcomes

  1. Pentadecanoic acid (C15:0)

    Process measure, biomarker of milk fast consumption, fatty acid in red blood cell membranes which comes primarily from milk fat

    Time frame: Change from start of trial (time of randomization) through end of trial (12 months)

  2. Heptadecanoic acid (C17:0)

    Process measure, biomarker of milk fast consumption, fatty acid in red blood cell membranes which comes primarily from milk fat

    Time frame: Change from start of trial (time of randomization) through end of trial (12 months)

  3. trans Palmitoleic acid (tC16:1ω-7)

    Process measure, biomarker of milk fast consumption, fatty acid in red blood cell membranes which comes primarily from milk fat

    Time frame: Change from start of trial (time of randomization) through end of trial (12 months)

  4. Alternative Healthy Eating Index (AHEI)

    Main outcome for Specific Aim #3, calculated using data from 24-hour dietary recalls

    Time frame: Change from start of trial (time of randomization) through end of trial (12 months)

  5. Milk intake

    Process outcome, measured by 24-hour dietary recalls

    Time frame: Change from start of trial (time of randomization) through end of trial (12 months)

  6. Nutrient profile

    Added sugars, saturated fat, fiber, calcium; measured by 24-hour dietary recalls

    Time frame: Change from start of trial (time of randomization) through end of trial (12 months)

  7. Food and beverage intake pattern

    Vegetables, fruits, legumes, and sugar-sweetened beverages; measured by 24-hour dietary recalls (Ancillary Study) Frequency of consuming between-meal-sugar-containing foods or beverages and consumption of foods (grams) with a high cariogenic potential, measured by 24-hour dietary recalls

    Time frame: Change from start of trial (time of randomization) through end of trial (12 months)

07

Study locations

1 of 1 sites recruiting
  • New Balance Foundation Obesity Prevention Center
    Boston, Massachusetts 02115, United States
    Recruiting
08

References and documents

Publications

  • Albala C, Ebbeling CB, Cifuentes M, Lera L, Bustos N, Ludwig DS. Effects of replacing the habitual consumption of sugar-sweetened beverages with milk in Chilean children. Am J Clin Nutr. 2008 Sep;88(3):605-11. doi: 10.1093/ajcn/88.3.605. PubMed 18779274 ↗
  • Ebbeling CB. Confusion at the milk cooler: opportunity to bolster the evidence base for preventive nutrition. Am J Clin Nutr. 2020 Feb 1;111(2):240-241. doi: 10.1093/ajcn/nqz319. No abstract available. PubMed 31901161 ↗
  • Willett WC, Ludwig DS. Milk and Health. N Engl J Med. 2020 Feb 13;382(7):644-654. doi: 10.1056/NEJMra1903547. No abstract available. PubMed 32053300 ↗

Individual participant data

Plan to share: Yes — We will share de-identified IPD on Open Science Framework.

Supporting information: Study protocol, Analytic code

Time frame: The Study Protocol will be posted prior to enrollment of the first study participant. The IPD and Analytic Code for each peer reviewed manuscript from the study will be posted at the time of publication.

Access criteria: The data will be available to any interested party through Open Science Framework.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2022 (actual). Primary completion is estimated for Dec 2026, 48 months after the start.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 48 months is above that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2022
First posted
Jul 19, 2022
StartActual
Dec 28, 2022
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Jan 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05464186
Responsible party
Cara B Ebbeling (Co-Director, New Balance Foundation Obesity Prevention Center; Associate Professor of Pediatrics, Boston Children's Hospital) — Principal investigator
First posted
Jul 19, 2022
Start date
Dec 28, 2022
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jan 8, 2026

Study contacts

Donna L Lesperance, MA, MPH
Contact
Donna.Lesperance@childrens.harvard.edu
617-919-7305
Cara B Ebbeling, PhD
principal investigator · Boston Children's Hospital
David S Ludwig, MD, PhD
principal investigator · Boston Children's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion